An interventional study of Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences and Video on the importance of good oral health for patients with AIRD in Rheumatologic Disease and Autoimmune Diseases, sponsored by University of Alabama at Birmingham. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.
Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 9th largest by planned enrollment of the 243 interventional ones that give a count, is one of 23 that started in 2024, is one of 29 with no phase, reaches primary completion later than 39 of the 111 other live ones, and was the 296th registered.
804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.
Browse Autoimmune Diseases studies →91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
iCell Gene Therapeutics · Sites in United States
Ages 16–70
University of Washington · Sites in United States, Netherlands
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
341 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 100 · Phase 3 47 · Phase 4 12
First in 1991; this study’s year is marked. 23 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,170 is above the median of 40 across 543 interventional studies indexed under Autoimmune Diseases.
Median enrollment 53 across the 243 interventional studies, 420 across the 95 observational. Of the 209 that completed or were terminated, 79 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 341 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 3 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
34 of the studies in Autoimmune Diseases with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
Add all 34 to your calendar (.ics) → With an account.
Among the 341 studies in Autoimmune Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.
Black and Latinx persons are at higher risk for certain autoimmune and inflammatory rheumatic diseases (AIRD) and have experienced worse COVID-19 outcomes compared to their white counterparts. Given the risks of severe COVID-19 outcomes such as hospitalization and death in people with AIRD, COVID-19 vaccine is recommended in this population. Historically, overall vaccine uptake among people with AIRDs has been low, and this vaccine reluctance has extended to COVID-19 vaccination. While additional COVID-19 vaccine doses have offered considerable added protection against severe outcomes, only 20% of all vaccinated persons in Alabama (AL) and 45% in Massachusetts have obtained an additional dose of COVID-19 vaccine as of October 2022. Racial and ethnic minority groups have faced disparities in obtaining subsequent COVID-19 vaccines, particularly in under-resourced communities, including those in Alabama, Massachusetts, and Illinois. Together, these obstacles exacerbate existing health inequities among people of color and perpetuate worse COVID-19 outcomes.
We will conduct a randomized controlled study to test an intervention that seeks to address gaps in COVID-19 vaccine information and access inequities common in Black and Latinx populations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Lack of access to phone
Participants will review video with narratives on COVID-19 vaccination in patients with AIRD, receive brochure on the same topic; and interact with patient navigators.
Behavioral: Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences · Behavioral: Brochure on COVID-19 vaccination in AIRD patients · Behavioral: Patient Navigation
Participants will review video on the importance of oral health in patients with AIRD and receive brochure on the same topic.
Behavioral: Video on the importance of good oral health for patients with AIRD · Behavioral: Brochure on the importance of good oral health in AIRD patients
Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD
Participants will watch video on the importance of good oral health in AIRD patients.
Also known as: Attention Control
Participants
Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD
Participants will receive a brochure on the importance of good oral health in AIRD patients.
Receipt of updated COVID-19 vaccination.
We will measure rates of receipt of updated COVID-19 vaccination.
Time frame: 3 months
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.
Of 78 non-industry interventional studies with no phase under Autoimmune Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 62. This study's planned 32 months is close to that.
Counting every sponsor, half of 87 studies reached it within 31 months; a quarter within 15 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →